Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

October 03, 2005 09:00 ET

Novadaq to Present at Sachs-Bloomberg and BioContact

TORONTO, ONTARIO--(Marketwire - Oct. 3, 2005) - Novadaq® Technologies Inc. (TSX:NDQ) today announced corporate presentations at two financial conferences. Arun Menawat, President and Chief Executive Officer will present a corporate overview at the Sachs-Bloomberg 5th Annual Biotech in Europe Investor Forum in Zurich, Switzerland on Tuesday, October 4, 2005. Rick Mangat, Vice President Operations, will also present a corporate overview at BioContact Québec, at the Château Frontenac, Québec City at 10:30 a.m. on Thursday, October 6, 2005.

About Sachs-Bloomberg 5th Annual Biotech in Europe Investor Forum

Biotech in Europe Investor Forum is a high profile life sciences event organized in association with Bloomberg L.P. and attended by an executive level audience of investors, pharmas, fund managers and capital raising companies. Running over two days, the event provides roundtables on key industry and scientific developments as well as finance and investment trends.

About BioContact Quebec 2005

BioContact Québec 2005 is a biopharmaceutical partnership symposium gathering over 1200 participants. More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics, and services) and disciplines. For more information, please visit www.biocontact.qc.ca.

About Novadaq Technologies

Novadaq Technologies (TSX:NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY® Intra-operative Imaging System enables surgeons to visually assess coronary vasculature and bypass graft functionality during the course of CABG surgery. Novadaq's ophthalmic product, the OPTTX™ System, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System is currently being evaluated in clinical trials.

For more information, please visit the company's website at www.novadaq.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information